News

Novel Natural History Study to answer question in Rare Disease

Phase II trial for Zymenex lethal disease treatment candidate

Zymenex in Phase I/II clinical trial in seriously ill children with MLD

Zymenex has recieved a gracious grant from the MLD Foundation (USA)

Zymenex to focus on the Lysosomal Storage Disease, Metachromatic Leukodystrophy (MLD)...

Zymenex granted European Patent...

New Board Chairman of Zymenex...

Appointment of new Director of Clinical Operations...

Zymenex has received Orphan Drug Designation...

HemeBiotech changes name to Zymenex and strengthens its Board of Directors..